HeartSciences Inc. (NASDAQ:HSCS) Short Interest Update

HeartSciences Inc. (NASDAQ:HSCS) was the recipient of a significant decline in short interest in the month of August. As of August 14th, there was short interest totaling 50,682 shares, a decline of 33.3% from the July 30th total of 76,030 shares. Based on an average daily trading volume, of 66,843 shares, the short-interest ratio is presently 0.8 days. Approximately 1.4% of the company’s shares are sold short.

HeartSciences Stock Down 1.0%

Shares of HSCS stock traded down $0.03 during trading hours on Tuesday, hitting $3.12. 63,198 shares of the company’s stock traded hands, compared to its average volume of 881,764. The stock’s fifty day simple moving average is $2.53 and its two-hundred day simple moving average is $2.35. HeartSciences has a 12-month low of $1.63 and a 12-month high of $3.80. The stock has a market cap of $12.17 million, a price-to-earnings ratio of -0.79 and a beta of 1.79.

HeartSciences (NASDAQ:HSCS) last posted its quarterly earnings results on Thursday, July 23rd. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.66) by ($0.22). On average, equities analysts forecast that HeartSciences will post -3.04 earnings per share for the current fiscal year.

Hedge Funds Weigh In On HeartSciences

An institutional investor recently raised its stake in HeartSciences stock. DRW Securities LLC lifted its stake in HeartSciences Inc. (NASDAQ:HSCS) by 13.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 95,065 shares of the company’s stock after purchasing an additional 11,455 shares during the quarter. DRW Securities LLC owned 2.99% of HeartSciences worth $294,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 17.24% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of HeartSciences in a research report on Wednesday, June 24th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, HeartSciences has a consensus rating of “Hold” and an average price target of $8.00.

HeartSciences Company Profile

HeartSciences, Inc (NASDAQ: HSCS) is a medical device company focused on the development and commercialization of advanced, non‐invasive cardiac diagnostic technologies. The company’s flagship product, MyoVista, is a high‐fidelity electrocardiograph (ECG) designed to detect subtle changes in cardiac function that may indicate myocardial ischemia or left ventricular dysfunction. By leveraging high‐frequency wavelet analysis within the QRS complex, MyoVista provides clinicians with enhanced visualization and analytical capabilities that extend beyond those of standard ECG systems.

HeartSciences supports the MyoVista system with an integrated software suite that automates data analysis and report generation, facilitating seamless integration into existing clinical workflows.